Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 19, 2026HaematologicaOpen Access

P54 | Evolving Outcomes in Multiple Myeloma Real-World Practice: 30-Years Single Center Experience

View Full Paper
Ask AI
Bookmark
Share

Authors

GGG. GiuntaUniversity of CataniaCBC. BellofiorePoliclinico Universitario di CataniaESE. ScalisiUniversity of Catania

Discussion

Loading...

Member takes

Implication

This analysis demonstrates improved outcomes in multiple myeloma patients over three decades, highlighting therapeutic advancements and their benefits.

Key Points

  • To evaluate treatment patterns and survival outcomes of multiple myeloma patients over a 30-year period.
  • Evaluated 1052 multiple myeloma patients treated at a single center between 2005 and 2025.
  • Divided patients into two cohorts based on diagnosis year: Group A (2005-2015) and Group B (2016-2025).
  • Assessed overall survival and time to next treatment using real-world data.
  • Median overall survival for the entire cohort was 65 months.
  • Patients under 65 years old in Group B had a superior median OS compared to Group A.
  • ASCT recipients showed longer overall survival across both groups, particularly in Group B.
  • Clinical trial participants experienced significant OS benefits across cohorts.

Cite This Study

Giunta et al. (2026) studied this question.

synapsesocial.com/papers/69e4702d010ef96374d8d75ehttps://doi.org/10.3324/haematol.2026.s2.14085
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1P51 | EVOLVING ATTRITION RATES IN MULTIPLE MYELOMA REAL-WORLD PRACTICE OVER A 30-YEARS PERIOD FROM A SINGLE CENTER EXPERIENCE2026
  2. 2P24 | APPROACHING CURE IN MULTIPLE MYELOMA: A DUAL-CENTER EXPERIENCE AMONG PATIENTS DIAGNOSED BEFORE 20102026 · 1 citations
  3. 3Survival outcomes of multiple myeloma patients previously exposed to BCMA-targeted therapies in the honeur european network2025
  4. 4Two decades of landscape change in the treatment of multiple myeloma.2026
  5. 5Updated analysis of survival and treatment evolution in european multiple myeloma patients (2012–2023) across 7 countries from the honeur network2025